Stents for malignant ureteral obstruction

doi:10.1016/j.ajur.2016.04.002

Asian Journal of Urology, 2016, 3 (3): 142-149 doi: 10.1016/j.ajur.2016.04.002

Review

Current Issue | Archive | Adv Search

Stents for malignant ureteral obstruction

Kristina Pavlovic, Dirk Lange, Ben H. Chew

Department of Urologic Sciences, The Stone Centre at Vancouver General Hospital, University of British Columbia, Vancouver, Canada

Abstract
Related Citation (2)

Download:

HTML

PDF (956KB)
Export: BibTeX | EndNote (RIS)

Abstract Malignant ureteral obstruction can result in renal dysfunction or urosepsis and can limit the physician's ability to treat the underlying cancer. There are multiple methods to deal with ureteral obstruction including regular polymeric double J stents (DJS), tandem DJS, nephrostomy tubes, and then more specialized products such as solid metal stents (e.g., Resonance Stent, Cook Medical) and polyurethane stents reinforced with nickel-titanium (e.g., UVENTA stents, TaeWoong Medical). In patients who require long-term stenting, a nephrostomy tube could be transformed subcutaneously into an extra-anatomic stent that is then inserted into the bladder subcutaneously. We outline the most recent developments published since 2012 and report on identifiable risk factors that predict for failure of urinary drainage. These failures are typically a sign of cancer progression and the natural history of the disease rather than the individual type of drainage device. Factors that were identified to predict drainage failure included low serum albumin, bilateral hydronephrosis, elevated C-reactive protein, and the presence of pleural effusion. Head-to-head studies show that metal stents are superior to polymeric DJS in terms of maintaining patency. Discussions with the patient should take into consideration the frequency that exchanges will be needed, the need for externalized hardware (with nephrostomy tubes), or severe urinary symptoms in the case of internal DJS. This review will highlight the current state of diversions in the setting of malignant ureteral obstruction.

Key words： Malignant ureteral obstruction Ureteral stent Hydronephrosis

Received: 02 March 2016 Published: 05 July 2016

Corresponding Authors: Ben H. Chew E-mail: ben.chew@ubc.ca

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Kristina Pavlovic
	Dirk Lange
	Ben H. Chew

TRENDMD:

Cite this article:

Kristina Pavlovic,Dirk Lange,Ben H. Chew. Stents for malignant ureteral obstruction[J]. Asian Journal of Urology, 2016, 3(3): 142-149.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2016.04.002 OR http://www.ajurology.com/EN/Y2016/V3/I3/142

[1]	Yu SH, Ryu JG, Jeong SH, Hwang EC, Jang WS, Hwang IS, et al. Predicting factors for stent failure-free survival in patients with a malignant ureteral obstruction managed with ureteral stents. Korean J Urol 2013;54:316-21.
[2]	Chung HH, Kim MD, Won JY, Won JH, Cho SB, Seo TS, et al. Multicenter experience of the newly designed covered metallic ureteral stent for malignant ureteral occlusion: comparison with double J stent insertion. Cardiovasc Interv Radiol 2013;37:463-70.
[3]	Chow PM, Chiang IN, Chen CY, Huang KH, Hsu JS, Wang SM, et al. Malignant ureteral obstruction: functional duration of metallic versus polymeric ureteral stents. PLoS One 2015;10: e0135566.
[4]	Kulkarni R. Metallic stents in the management of ureteric strictures. Indian J Urol 2014;30:65-72.
[5]	Kim KS, Choi S, Choi YS, Bae WJ, Hong SH, Lee JY, et al. Comparison of efficacy and safety between a segmental thermo-expandable metal alloy spiral stent (Memokath 051) and a self-expandable covered metallic stent (UVENTA) in the management of ureteral obstructions. J Laparoendosc Adv Surg Tech A 2014;24:550-5.
[6]	Kadlec AO, Ellimoottil CS, Greco KA, Turk TM. Five-year experience with metallic stents for chronic ureteral obstruction. J Urol 2013;190:937-41.
[7]	Chow PM, Hsu JS, Wang SM, Yu HJ, Pu YS, Liu KL. Metallic ureteral stents in malignant ureteral obstruction: short-term results and radiological features predicting stent failure in patients with non-urological malignancies. World J Urol 2014; 32:729-36.
[8]	Abbasi A, Wyre HW, Ogan K. Use of full-length metallic stents in malignant ureteral obstruction. J Endourol 2012;27: 640-5.
[9]	Elsamra SE, Motato H, Moreira DM, Waingankar N, Friedlander JI, Weiss G, et al. Tandem ureteral stents for the decompression of malignant and benign obstructive uropathy. J Endourol 2013;27:1297-302.
[10]	Varnavas M, Bolgeri M, Mukhtar S, Anson K. The role of tandem double-J ureteral stents in the management of malignant ureteral obstruction. J Endourol 2016;30:465-8.
[11]	Allen DJ, Longhorn SE, Philp T, Smith RD, Choong S. Percutaneous urinary drainage and ureteric stenting in malignant disease. Clin Oncol R Coll Radiol 2010;22:733-9.
[12]	Alawneh A, Tuqan W, Innabi A, Al-Nimer Y, Azzouqah O, Rimawi D, et al. Clinical factors associated with a short survival time after percutaneous nephrostomy for ureteric obstruction in cancer patients: an updated model. J Pain Symptom Manag 2016;51:255-61.
[13]	Monsky WL, Molloy C, Jin B, Nolan T, Fernando D, Loh S, et al. Quality-of-life assessment after palliative interventions to manage malignant ureteral obstruction. Cardiovasc Interv Radiol 2013;36:1355-63.
[14]	Ishioka J, Kageyama Y, Inoue M, Higashi Y, Kihara K. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J Urol 2008; 180:618-21. discussion 21.
[15]	Azuma T, Nagase Y, Oshi M. Prognostic marker for patients with malignant ureter obstruction. Clin Genitourin Cancer 2013;11:353-6.
[16]	Kimuli M, Sciberras J, Lloyd S. In: Göőz PM, editor. Extraanatomic urinary drainage for urinary obstruction, chronic kidney disease. Rijeka, Croatia: InTech; 2012. p. 281-96. http://dx.doi.org/10.5772/23049.
[17]	Chung KJ, Park BH, Park B, Lee JH, Kim WJ, Baek M, et al. Efficacy and safety of a novel, double-layered, coated, selfexpandable metallic mesh stent (Uventa) in malignant ureteral obstructions. J Endourol 2013;27:930-5.
[18]	Kim KH, Cho KS, Ham WS, Hong SJ, Han KS. Early application of permanent metallic mesh stent in substitution for temporary polymeric ureteral stent reduces unnecessary ureteral procedures in patients with malignant ureteral obstruction. Urology 2015;86:459-64.
[19]	Taylor ER, Benson AD, Schwartz BF. Cost analysis of metallic ureteral stents with 12 months of follow-up. J Endourol 2012; 26:917-21.
[20]	Frederick L, Kadlec AO, Shah A, Ellimoottil CS, Turk TM, Schwartz BF. Cost analysis of metallic stents for chronic ureteral obstruction: a multi-center study. J Urol Clin Pract 2016[in press].
[21]	Baumgarten AS, Hakky TS, Carrion RE, Lockhart JL, Spiess PE. A single-institution experience with metallic ureteral stents: a cost-effective method of managing deficiencies in ureteral drainage. Int Braz J Urol 2014;40:225-31.
[22]	Wijayarathna S, Suvendran S, Ishak M, Weligamage A, Epa A, Munasinghe S, et al. Outcome of retrograde ureteric stenting as a urinary drainage procedure in ureteric obstruction related to malignant lesions. Ceylon Med J 2015;59:124-7.
[23]	Garg RK, Menon P, Narasimha Rao KL, Arora S, Batra YK. Pyeloplasty for hydronephrosis: issues of double J stent versus nephrostomy tube as drainage technique. J Indian Assoc Pediatr Surg 2015;20:32-6.
[24]	Song SH, Pak S, Jeong IG, Kim KS, Park HK, Kim CS, et al. Outcomes of stent-change therapy for bilateral malignancyrelated ureteral obstruction. Int Urol Nephrol 2014;47: 19-24.
[25]	Kouba E, Wallen EM, Pruthi RS. Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol 2008;180:444-50.
[26]	Chow PM, Hsu JS, Huang CY, Wang SM, Lee YJ, Huang KH, et al. Metallic ureteral stents in malignant ureteral obstruction: clinical factors predicting stent failure. J Endourol 2014; 28:729-34.